Detalles de la búsqueda
1.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
N Engl J Med;
372(5): 426-35, 2015 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-25629741
2.
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Br J Haematol;
176(1): 76-85, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27858987
3.
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Blood;
125(25): 3868-77, 2015 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25934475
4.
Reimagining diversity in multiple myeloma clinical trials.
Hematol Oncol;
40(4): 689-694, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35391496
5.
Addressing racial/ethnic disparities in cancer clinical trials: Everyone has a role to play.
Cancer;
127(18): 3282-3289, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33904590
6.
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in ß-thalassemia major (CORDELIA).
Blood;
123(10): 1447-54, 2014 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24385534
7.
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Haematologica;
101(7): 821-9, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27102499
8.
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Eur J Haematol;
97(2): 192-200, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26608702
9.
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent ß thalassaemia.
Br J Haematol;
168(6): 882-90, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25402221
10.
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Br J Haematol;
168(2): 284-90, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25212456
11.
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.
Eur J Haematol;
95(3): 244-53, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25418187
12.
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Am J Hematol;
90(2): 91-6, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25345697
13.
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
Magn Reson Med;
71(6): 2215-23, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23821350
14.
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Blood;
120(5): 970-7, 2012 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-22589472
15.
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Eur J Haematol;
92(6): 521-6, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24460655
16.
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia.
Oncol Ther;
12(1): 115-129, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38064162
17.
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
Br J Haematol;
182(2): 279-284, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29984424
18.
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.
Haematologica;
98(7): 1045-8, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23585526
19.
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Ann Hematol;
92(11): 1485-93, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23775581
20.
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Am J Hematol;
88(12): 1068-73, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23946212